Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA OKs Medtronic's fluid-monitoring HF (heart failure) device:

This article was originally published in Clinica

Executive Summary

The US FDA has approved Medtronic's InSync Sentry cardiac resynchronisation therapy (CRT) defibrillator system, the first CRT device that can automatically alert clinicians to changes in fluid accumulation in the lungs and thoracic cavity. Most hospital admissions for heart failure (HF) are due to fluid accumulation in the thorax, which often goes undetected until the patient is critically ill. Such patients can require urgent treatment in hospital, posing a tremendous cost burden to healthcare systems. The InSync Sentry provides an early warning of worsening symptoms before hospitalisation is critical, allowing physicians to adjust patient treatment proactively. It monitors fluid status using a feature called OptiVol, which measures changes in intra-thoracic impedance, an indication of changing fluid volume. The device was released in Europe earlier this year and will be launched in the US early next year.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts